Introduction
Age-related macular degeneration (AMD) is the leading cause of irreversible blindness in people 50 years of age or older in the developed world [1, 2] . Although an estimated 80% of patients with AMD have the nonneovascular form [3], the neovascular (wet or exudative) form is responsible for almost 90% of severe visual loss (visual acuity 20/200 or worse) resulting from AMD [4] .
Treatment options for people with neovascular AMD are limited. Although laser photocoagulation and photodynamic therapy (PDT) with verteporfin could be effective in treating lesions for specific subgroups of patients, they do not prevent new choroidal neovascularization (CNV) formation.
Antiangiogenic therapy, for example, antivascular endothelial growth factor (anti-VEGF), which aims to prevent further CNV rather than only destroy it, is the latest approach to the treatment of neovascular AMD. Currently, the most commonly used VEGF antagonists are ranibizumab (Lucentis; Genentech Inc., South San Francisco, California, USA) and bevacizumab (Avastin).
Ranibizumab, which is an antibody fragment from the bevacizumab molecule with an increased binding affinity for all forms of VEGF, has been approved for the treatment of all angiographic subtypes of subfoveal neovascular AMD by the Food and Drug Administration and by the European Medicines Agency since 2006 and 2007, respectively. The costs of ranibizumab, however, are immense. Using monthly injections with a dose of 0.5 mg, the annual costs come to more than US$23 000 per patient [5] .
In contrast to ranibizumab, bevacizumab was not developed for the treatment of AMD and consequently has no approval for this use. Bevacizumab is approved for the treatment of specific cancers, for example, metastatic colon and rectum cancer. Even before ranibizumab was licensed, bevacizumab had been used as an off-label treatment for AMD. The first report of intravitreal bevacizumab (IVB) administration for neovascular AMD was published in 2005 [6] . After this initial report, numerous case series that (apparently) support the efficacy and safety of bevacizumab were published. The costs of IVB are much less than those for ranibizumab. Small aliquots in syringes for intraocular injections can be prepared for about US$17-50 a month ( US$600 annually) [5] . The cost difference is so striking that it is not surprising that even groups who strongly believe in a regulated drug development process tolerate off-label use.
The need for a review
We conducted a systematic review to evaluate whether the existing evidence justifies the intravitreal use of bevacizumab in neovascular AMD. In this context, we evaluated efficacy and safety of off-label bevacizumab in comparison to ranibizumab.
Systematic literature search
We searched Medline (Ovid), Embase and the Cochrane Library without date limit [main search for randomized clinical trials (RCTs): August 09]. The searches were supplemented by handsearching the bibliographies of included studies and reviews and by contacting the pharmaceutical manufacturer (Genentech) of ranibizumab and bevacizumab. Currently conducted RCTs comparing Avastin with Lucentis were searched both in the register for clinical trials (http://clinicaltrials.gov/) and in the WHO International Clinical Trials Registry Platform (http://www.who.int/ictrp/en/).
Study selection
Included were RCTs that evaluated IVB or ranibizumab as monotherapy against any other treatment in patients with exudative AMD. Case series were included if they enrolled a minimum of 10 patients and met predefined quality standards; that is, the publication had to provide adequate information regarding patient selection criteria or the selection of patients had to be consecutive.
Studies that included patients with other indications than exudative AMD, patients previously treated with VEGF inhibitors or patients receiving systemic treatment were excluded.
Data extraction and quality assessment
Titles and abstracts were reviewed using the selection criteria described above. Full papers of appropriate studies were obtained for detailed evaluation. For the evaluation of RCTs and case series, a modified quality evaluation tool of the Center for Reviews and Dissemination was used [7] . For example, information on the number of participants, follow-up times, masking of outcome assessor, ascertainment of exposure (e.g., dosage and frequency of drug administered) and outcome measurements, and transparency of patient flow were extracted.
All stages of study selection, data extraction and quality assessment were performed independently by two reviewers (C.S., M.L. or C.E.). Any disagreement was resolved by discussion and consensus.
Results of the search
After removing duplicate references, the searches identified 3628 citations. The inclusion criteria were met by four RCTs (11 publications [8 ,9,10,11 ,12 ,13-16,17 ,18]) evaluating ranibizumab vs. PDT, sham or usual care with a total of 1392 patients and four RCTs (five publications [19] [20] [21] 22 ,23]) evaluating bevacizumab vs. PDT AE triamcinolone with a total of 287 patients. In addition, 25 case series 48 ] examining bevacizumab including a total of 2519 patients were analyzed.
Ranibizumab: study characteristics
Characteristics of the RCTs evaluating intravitreal ranibizumab are presented in [17 ] . In contrast to the MARINA study, treated patients received ranibizumab injections once monthly for 3 consecutive months, followed by a dose administered once every 3 months (follow-up time: 12 months). In the study of Heier 2006 [18] , 64 patients were randomized to monthly ranibizumab with varying doses for 3 months or usual care (i.e., PDT in predominantly classic lesions and observation in all other lesions). After 3 months, patients could continue their regimen for 3 additional months or cross over to the alternative treatment.
All RCTs evaluating ranibizumab were multicenter trials. The ANCHOR 2009 [8 ] , MARINA 2006 [13] and PIER 2008 [17 ] study were sponsored by the pharmaceutical industry. In the study of Heier 2006 [18] , the source of funding was not reported.
No case series evaluating ranibizumab met our inclusion criteria.
Bevacizumab: study characteristics Table 1 shows study characteristics of RCTs evaluating IVB. Bashshur [19] randomized 64 patients to PDT or bevacizumab injections pro re nata. The patients were followed up for 6 months. The 3-month study of Lazic and Gabric [20] enrolled 165 patients and compared a single bevacizumab injection with a single PDT session or a combination therapy. Hahn et al. [21] used PDT in combination with triamcinolone as comparator and enrolled 30 patients. The patients received bevacizumab injections once monthly for 3 months. Sacu and coworkers [22 ,23] also used PDT in combination with triamcinolone and included 28 patients. The patients received bevacizumab injections once monthly for 3 consecutive months, followed by a dose administered pro re nata. Follow-up time was 12 months.
All RCTs evaluating bevacizumab were monocenter trials. Two studies reported that no pharmaceutical sponsor was involved [19, 21] , and two studies (three publications) did not provide data on the source of funding [20,22 ,23] .
In total, 13 prospective [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] and 12 retrospective [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] 48 ] case series evaluating bevacizumab were analyzed ( Table 2 ). The number of included patients ranged between 12 and 625 (median: 48). Patients received between one and four IVB injections (median: 2) and the applied dosage of bevacizumab varied between 1.0 and 2.5 mg (median: 1.25 mg). Minimum follow-up time was 1 month and maximum follow-up time 15 months. Two case series were multicenter studies [47, 48 ]. The remaining publications were conducted in one center. Funding sources were specified in 11 publications [26, [29] [30] [31] [33] [34] [35] 38, 41, 45, 47] . A pharmaceutical sponsor, however, was not reported.
Ranibizumab: outcome, effectiveness
At 24 months, approximately 90% of patients treated with monthly ranibizumab injections (0.3 and 0.5 mg) showed stable acuity, compared with 66 and 53% in the control arms (PDT and sham, respectively) [8 ,13] . In addition, between 34 [13] and 40% [8 ] of patients treated with 0.5 mg ranibizumab gained 15 or more letters of visual acuity, compared with approximately 220 Retinal, vitreous and macular disorders 5% of patients receiving sham or PDT treatment.
Patients from the PIER 2008 study treated with ranibizumab showed an initial increase in mean visual acuity during the first 3 months, when ranibizumab was administered monthly [17 ] . However, after this period, when ranibizumab was administered quarterly, visual acuity decreased and returned to baseline at 12 months. The study of Heier 2006 [18] showed an increase of 15 letters or more in 20-30% of patients treated with ranibizumab, whereas in the control arm, no increase in visual acuity was observed after 3 months.
Bevacizumab: outcome, effectiveness
Compared with PDT [AE intravitreal triamcinolone (IVTA)], bevacizumab showed a relative improvement in visual acuity that is of similar size as in the comparison of ranibizumab with PDT (relative improvement 30-35%) after 6 and 12 months, respectively [19,22 ,23] .
None of the case series evaluating bevacizumab reported a significant decrease in visual acuity 48 ] .
Ranibizumab: outcome, safety
Ocular adverse events are displayed in Table 3 . Intravitreal ranibizumab injections have been associated with endophthalmitis ( 2.1%), uveitis ( 1.3%), retinal detachment ( 1.5%), retinal tear ( 1.9%), vitreous hemorrhage ( 8.0%) and traumatic lens damage ( 0.4%) [8 ,13,18] . In addition, all trials reported a transient increase in intraocular pressure in the study eye after intravitreal injections. Nonocular adverse events are presented in Table 4 . Overall, none of the RCTs evaluating ranibizumab showed a statistical difference among the treatment groups in the rates of serious nonocular adverse events, including those known to be potentially associated with systemic administration of anti-VEGF agents in the cancer treatment setting. The rate of key arterial nonfatal thromboembolic events (myocardial infarction and stroke) during the first and second year of the ANCHOR 2009 and MARINA 2006 trials was numerically, but not statistically significantly higher in the 0.5 mg ranibizumab arm than in the control arm (3.6 [8 ] and 2.5% [13] , respectively vs. 1.4 and 0.8%, respectively). In the ANCHOR 2009, MARINA 2006 and PIER 2008 study, the incidence of serious nonocular hemorrhage (such as gastrointestinal hemorrhage, traumatic subdural hematoma and duodenal ulcer hemorrhage) was also numerically higher in the ranibizumab than in the control groups [2.9% (0.3 mg; [8 ] ), 2.1% (0.5 mg; [13] ) and 0.6% (0.5 mg; [17 ] ) vs. 0.7, 0.8 and 0.0%]. Treatment-emergent hypertension was not more common in the ranibizumab than in the control groups [8 ,13,17 ] . As the ranibizumab studies were not powered to detect small differences in rates, no conclusion can be drawn regarding whether these differences were drug-related or due to chance alone.
Bevacizumab: outcome, safety
IVB injections have not been associated with major ocular adverse events such as endophthalmitis, uveitis, retinal detachment, lens damage and vitreous hemorrhage in the published RCTs (Table 3) . A transient increase in intraocular pressure after the injections was also not reported. However, an increased rate of pigment epithelial tears (5.5 vs. 0.0%), posterior vitreous detachment (14.6 vs. 0.0%) and cataract progression (7.3 vs. 0.0%) was reported in one RCT evaluating bevacizumab [20] .
IVB injections have not been associated with any systemic adverse events in RCTs (Table 4) .
Regarding ocular adverse events, four case series reported an increased rate of endophthalmitis (range between 0.2 [42] and 0.9% [38, 45] ). An increased rate of retinal pigment epithelial tears (rips) was observed in six reports [34, 35, 37, 38, 40, 45] (range between 0.9 [45] and 7.5% [37] ). Vitreous detachment was reported in 9.8% of patients in one publication [35] and an increased rate of submacular hemorrhage was observed in three case series (2.7 [38] , 7.5 [41] and 1.5% [44] ). Moreover, in the retrospective case series of Wu et al. [48 ] , an increased rate of uveitis (0.3%), retinal detachment (0.6%) and vitreous hemorrhage (0.08%) was reported. Seven case series reported minor ocular adverse events, such as pain [31] , conjunctival hyperemia [31] , subconjunctival hemorrhage 222 Retinal, vitreous and macular disorders Table 3 Rates of ocular adverse events under ranibizumab and bevacizumab/randomized clinical trials This number refers to adverse events that occurred in !5% of pooled ranibizumab-treated patients (i.e., !3 patients) during part I and part II of the study. Table 4 Rates of systemic adverse events under ranibizumab and bevacizumab/randomized clinical trials This number refers to serious nonocular hemorrhage adverse events. [24, 27, 31, 32, 48 ] , mild intraocular inflammation [24] , transient corneal epitheliopathy [34] and transient blurred vision [35] .
Nonocular adverse effects were observed in one retrospective case series [48 ] . The incidence of cerebrovascular accidents and myocardial infarct was 0.3% and the incidence of acute hypertension was 1.5%. In addition, 0.6% of patients with exudative AMD showed an iliac artery aneurysm.
Ranibizumab: outcome, quality of life
Two RCTs (three publications [11 ,12 ,16] ) examined the effect of ranibizumab on patient-reported visual functions using the national Eye Institute Visual Function Questionnaire 25 after 12 and 24 months, respectively [49] . Ranibizumab-treated patients were more likely to improve in near activities, distance activities and vision-specific dependency (e.g., driving, mental health, social function) than patients receiving sham treatments through 24 months.
Bevacizumab: outcome, quality of life
No adequate data are available providing information on the quality of life under the treatment of bevacizumab.
Methodological limitations
In contrast to the studies evaluating ranibizumab, the existing RCTs evaluating bevacizumab do not meet the quality requirements of phase III trials. Validity is limited by small sample sizes (between 28 and 165 patients per study), inadequate masking, lack of standardized vision measurements and missing intention-to-treat analyses. Also, nothing is known about long-term (>12 months) improvements in visual acuity and optimal treatment intervals for bevacizumab.
Regarding safety, it seems -when reading the current literature uncritically -that ocular and systemic adverse events are acceptable using bevacizumab. For example, in contrast to the studies evaluating ranibizumab, very few publications reported severe ocular adverse effects (e.g., endophthalmitis) or systemic complications under bevacizumab treatment. But again, this finding could be misleading, in particular, due to inadequate reporting (e.g., the patient flow was described insufficiently in more than half of the cited case series [24, 27, 28, 30, 34, 35, 37, 38, [41] [42] [43] [44] [45] [46] [47] ), the low number of received injections, small sample sizes, short follow-up times and an unsystematic evaluation of adverse effects [e.g., the multicenter Pan-American Collaborative Retina Study Group (PACORES) assessed systemic complications, if the patients were unable to attend, by telephone interview [48 ] ] in both RCTs and the often cited case series.
Discussion
The cost difference between ranibizumab and bevacizumab is so striking that the almost total lack of sound evidence from rigorously controlled clinical trials is simply ignored. Instead, numerous case series evaluating bevacizumab have been published over the last years. Not surprisingly, they show -similar to RCTs evaluating bevacizumab -common methodological weaknesses and are of limited validity. As there is no control group, no reliable conclusions on efficacy can be drawn from this study design. Regarding safety, the results are also of limited value because of -as cited above -inadequate reporting, an unsystematic evaluation of adverse effects and short follow-up times. Thus, the reported low rates of adverse effects for bevacizumab are not supported by reliable data. To date, no studies have been conducted on a quality level that would have allowed at least a crude estimation of adverse events under IVB.
Currently, there are no results of RCTs directly comparing the two VEGF inhibitors. As a result of large differences in the study quality, a reliable indirect comparison between bevacizumab and ranibizumab can also not be performed. Differences between ranibizumab and bevacizumab are likely. For example, the bevacizumab molecule is about three times as large as ranibizumab and may remain in the eye longer and, therefore, possibly allow for less frequent injections. In clinical practice, however, the same follow-up criteria are often applied for both drugs. Whether or not these treatment modalities are modifiable can only be decided after appropriate trials have generated reliable data.
The current situation is particularly complex because the distributors of both drugs, Novartis (Lucentis, Basel, Switzerland) and Roche (Avastin, Basel, Switzerland), and the manufacturer, Genentech, are not economically independent and, thus, have not shown any interest in funding such trials. Therefore, pharmaceutical industry-independent head-to-head studies such as the Randomised 
Conclusion
Given the lack of controlled data, the widespread off-label use of bevacizumab is not justified in clinical practice. On the other hand, a major challenge in the management of patients who require repeated anti-VEGF injections is the high cost of ranibizumab. This may lead to a situation in which patients are denied anti-VEGF therapy if off-label bevacizumab is not used. This dilemma underlines the need for head-to-head studies comparing both VEGF antibodies, or, at least, well controlled randomized trials evaluating IVB. In the meantime, patients and doctors should be aware of the insufficient safety data regarding IVB.
